Borensztajn, Dorine M.
Hagedoorn, Nienke N.
Carrol, Enitan D.
von Both, Ulrich
Emonts, Marieke
van der Flier, Michiel
de Groot, Ronald
Herberg, Jethro
Kohlmaier, Benno
Levin, Michael
Lim, Emma
Maconochie, Ian K.
Martinon-Torres, Federico
Nijman, Ruud G.
Pokorn, Marko
Rivero-Calle, Irene
Tsolia, Maria
van der Velden, Fabian J. S.
Vermont, Clementien
Zavadska, Dace
Zenz, Werner
Zachariasse, Joany M.
Moll, Henriette A.
Funding for this research was provided by:
Horizon 2020 Framework Programme (668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303, 668303)
Newcastle Hospitals NHS Foundation Trust
National Institute for Health Research Biomedical Research Centre
Article History
Received: 9 May 2022
Accepted: 29 June 2022
First Online: 7 July 2022
Declarations
:
: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.
: DB, UB, EC, ME, MF, NH, BK, FMT, HM, EL, ML, MP, IRC, MT, CV, DZ, and WZ report grants from the European Union Horizon 2020 research and innovation programme during the study conduct. MP reports a grant from Pfizer and financial support from Pfizer and Sanofi outside the submitted work. MF reports a grant from CSL Behring outside the submitted work. RN reports a grant from the National Institute for Health Research during the study conduct. ME reports financial support from the National Institute for Health Research Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust and Newcastle University during the study conduct. MT is a member of the Advisory Board of MSD and Pfizer, a member of the National Committee on Immunization Practices, and a member of the national Scientific Advisory Group for the management of the pandemic. All other authors declare no competing interests.